精華製藥(002349.SZ):南通公司利托那韋獲得化學原料藥上市申請批准通知書
格隆匯7月23日丨精華製藥(002349.SZ)公佈,近日,精華製藥集團股份有限公司孫公司精華製藥集團南通有限公司(簡稱“南通公司”)獲得國家藥品監督管理局核准簽發的利托那韋《化學原料藥上市申請批准通知書》。
利托那韋原料藥系南通公司利托那韋醫藥中間體的下游原料藥延伸品種,是一種抗病毒藥物,主要用於治療艾滋病,在新冠肺炎流行期間,利托那韋也作為治療新冠肺炎的主要藥物之一。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.